Functional Mitral Regurgitation in Heart Failure

Functional mitral regurgitation (FMR) in the setting of left ventricular (LV) dysfunction and heart failure portends a poor prognosis. Guideline-directed medical therapy remains the cornerstone of initial treatment, with emphasis placed on treatment of the underlying LV dysfunction, as FMR is a secondary phenomenon and a disease due to LV remodeling. Surgical correction of FMR is controversial because it typically does not address the underlying mechanism and etiology of the condition. However, new, minimally invasive transcatheter therapies, in particular the MitraClip system, have shown promise in the treatment of FMR in selected patients. This review will summarize the pathophysiology underlying FMR, the prognosis of patients with heart failure and FMR, and the various medical and procedural treatment options currently available and under investigation.
Source: Cardiology in Review - Category: Cardiology Tags: Symposium Source Type: research

Related Links:

A fair amount of effort is presently put towards the exploration of supplements derived from vitamin B3 compounds (nicotinamide, niacin, nicotinamide riboside) that act as precursors to enable the manufacture of nicotinamide adenine dinucleotide (NAD). NAD is an important component in mitochondrial activity, and levels decline with age. Some portion of the loss of mitochondrial function, implicated in the progression of many age-related conditions, is due to NAD insufficiency. There is a rich history of the use of high doses of vitamin B3 as an intervention, most of it predating modern understanding of the role of NAD in m...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
(European Society of Cardiology) Save the date for HFA Discoveries, the latest scientific platform of the European Society of Cardiology (ESC). Find out what's on the horizon for prevention and treatment during this innovative online event.Worldwide, an estimated 26 million people have heart failure.1 In Europe, one-year all-cause mortality rates for acute and chronic heart failure are 23.6% and 6.4%, respectively, and heart failure hospitalisation rates are 18.7% and 9.9%, respectively.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
(University of Arkansas) With funding from the National Institutes of Health, University of Arkansas researchers hope to develop the first therapeutic drug to regenerate heart tissue. The lesion-seeking drug, released through stent placement, could treat coronary blockages and prevent heart failure.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 28 May 2020Source: Preventive MedicineAuthor(s): Corinna A. Noel, Michael J. LaMonte, Mary B. Roberts, Deborah H. Pearlman, Hailey Banack, Matthew Allison, Aladdin H. Shadyab, Bernhard Haring, Deepika Laddu, Lisa Warsinger Martin, Patricia K. Nguyen, JoAnn E. Manson, Charles B. Eaton
Source: Preventive Medicine - Category: International Medicine & Public Health Source Type: research
AbstractEbstein anomaly comprises approximately 1% of all congenital heart diseases. It occurs when the tricuspid valve fails to properly delaminate from the right ventricle, resulting in a clinical spectrum of abnormal tricuspid valve morphology and right ventricular dysfunction. Due to the anatomy of the tricuspid valve and right ventricle, as well as associated right- and left-sided pathology, patients are at risk for both right and left ventricular failure and the associated symptoms of each. Ebstein patients are also at risk for atrial arrhythmias, due to the atrial enlargement intrinsic to the anatomy, as well as the...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
AbstractAdvances in surgery and pediatric care over the past decades have achieved improved survival for children born with congenital heart disease (CHD) and have produced a large, growing population of patients with adult congenital heart disease (ACHD). Heart failure has emerged as the leading cause of death and a major cause of morbidity among the ACHD population, while as little evidence supports the efficacy of guideline-directed medical therapies in this population. It is increasingly important that clinicians caring for these patients understand how to utilize mechanical circulatory support (MCS) in ACHD. In this r...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
AbstractPurpose of reviewThe burden of heart failure (HF) is a significant national and global public health problem, with prevalence rates on the rise. Given the significant morbidity, mortality, and healthcare costs attributable to HF, it is of utmost importance to utilize preventive strategies to prevent the development of HF. Therefore, we sought to address how a multi-modal risk assessment approach can be used to stratify patients for HF risk and guide implementation of therapeutic strategies to prevent HF.Recent findingsNew externally validated, multivariate prediction models for incident HF can be applied in the gen...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Depression is a frequent and debilitating comorbidity that affects heart failure (HF) patients. Up to 30% of HF patients suffer from depression and even more have depressive symptoms. Moreover, depression carries a risk for HF, especially in high ‐risk groups, and is significantly associated with worse quality of life and clinical outcomes. The pathophysiology of depression and HF is poorly understood, but both diseases share several mechanisms and risk factors, including dysregulation of platelet reactivity, inflammation, neuroendocrine f unction, arrhythmias, high‐risk behaviours, and social factors. Current HF guide...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Review Source Type: research
Conclusions: Transcatheter closure of paravalvular leaks is a feasible and safe procedure with high rates of technical, echocardiographic and clinical success in the short and medium term. It is an adequate therapeutic alternative, mainly in high surgical risk patients and multiples comorbidities. PMID: 32459208 [PubMed - as supplied by publisher]
Source: Archivos de Cardiologia de Mexico - Category: Cardiology Authors: Tags: Arch Cardiol Mex Source Type: research
We present the case of a patient without previous diagnosis of relapsing polychondritis who was referred to our Institute with heart failure secondary to aortic regurgitation, initially attributed to endocarditis. PMID: 32459198 [PubMed - as supplied by publisher]
Source: Archivos de Cardiologia de Mexico - Category: Cardiology Authors: Tags: Arch Cardiol Mex Source Type: research
More News: Cardiology | Heart | Heart Failure